GSK's new long-acting drug candidate for severe asthma, depemokimab, reduced the rate of severe attacks by 54% in a pair of phase 3 trials presented at the European Respiratory Society (ERS ...
The European Respiratory Summit in Mumbai marked a significant milestone in global respiratory care, fostering collaboration between the European Respiratory Society (ERS) and the Indian Chest Society ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback